Drugs Information Online
Drugs and diseases reference index

Drugs and diseases reference index
Search
EN

Drugs A-Z List

Diseases & Conditions A-Z List

Herbs & Supplements

Medical Dictionary

Full Article

Popular Drugs

Popular Diseases & Conditions

Drugs reference index «Ranibizumab»

Ranibizumab
Ranibizumab


Ranibizumab

Pronunciation: (RA-ni-BIZ-oo-mab)Class: Selective vascular endothelial growth factor antagonist

Trade Names:Lucentis- Ophthalmic injection 10 mg/mL

Pharmacology

Binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A), reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.

Pharmacokinetics

Absorption

Following monthly intravitreous administration, C max is below the concentration thought necessary to inhibit biological activity of VEGF-A by 50% (0.3 to 2.36 ng/mL).

Indications and Usage

Treatment of neovascular (wet) age-related macular degeneration.

Contraindications

Ocular or periocular infection; hypersensitivity to any component of the product.

Dosage and Administration

Adults

Ophthalmic 0.5 mg (0.05 mL) by intravitreous injection once a month.

General Advice

  • Withdraw 0.2 mL through a 5-micron 19-gauge filter needle attached to a 1 mL tuberculin syringe.
  • Replace filter needle with a 30-gauge × 12-inch needle for intravitreous injection.
  • Expel contents until the plunger tip is aligned with the 0.05 mL line mark on the syringe.
  • Prior to the injection, give adequate anesthesia and broad-spectrum microbicide.
  • Perform the intravitreous injection procedure under aseptic conditions, including use of sterile gloves, sterile drape, and a sterile eyelid speculum.
  • Following injection, monitor for elevated IOP and endophthalmitis.
  • Instruct patient to report any symptoms suggestive of endophthalmitis without delay.
  • Use each vial for the treatment of a single eye.

Storage/Stability

Store under refrigeration at 36° to 46°F. Do not freeze. Protect from light. Store in original carton until use.

Drug Interactions

None well documented.

Laboratory Test Interactions

None well documented.

Adverse Reactions

The ranges represent the minimum and maximum rates across 3 studies.

Cardiovascular

Hypertension/elevated BP (5% to 23%); arterial thromboembolic events (2% to 3%).

CNS

Headache (2% to 15%); dizziness (2% to 8%).

EENT

Conjunctival hemorrhage (43% to 77%); eye pain (17% to 37%); vitreous floaters (3% to 32%); retinal hemorrhage (15% to 26%); increased IOP (8% to 24%); vitreous detachment (7% to 22%); foreign body sensation in eye (6% to 19%); eye irritation (4% to 19%); intraocular inflammation (5% to 18%); blurred/decreased visual acuity (4% to 17%); increased lacrimation (3% to 17%); cataract, nasopharyngitis (5% to 16%); visual disturbance (0% to 14%); blepharitis (3% to 13%); eye pruritus, subretinal fibrosis (0% to 13%); detachment of the retinal pigment epithelium (1% to 11%); ocular hyperemia (5% to 10%); dry eye, maculopathy (3% to 10%); retinal exudates (1% to 9%); conjunctival hyperemia (0% to 9%); ocular discomfort, posterior capsule opacification (0% to 8%); increased IOP (less than 2%).

GI

Nausea (2% to 9%); constipation (3% to 7%).

Genitourinary

UTI (4% to 9%).

Hematologic-Lymphatic

Anemia (3% to 8%).

Musculoskeletal

Arthralgia (3% to 11%); back pain (1% to 10%); arthritis (0% to 8%).

Respiratory

Upper respiratory tract infection (2% to 15%); bronchitis, cough (3% to 10%); sinusitis (2% to 8%).

Miscellaneous

Influenza (2% to 10%); immunoreactivity (0% to 3%).

Precautions

Monitor

Monitor IOP and perfusion of the optic nerve following intravitreous injection.

Pregnancy

Category C .

Lactation

Undetermined.

Children

Safety and efficacy not established.

Endophthalmitis and retinal detachments

May occur.

Increased IOP

May occur within 60 min of intravitreous injection.

Thromboembolic events

Arterial thromboembolic events may occur.

Hepatic or renal function impairment

No studies have been conducted.

Overdosage

Symptoms

Doses as high as 2 mg have been tolerated.

Patient Information

  • Advise patient to seek immediate care from an ophthalmologist if the eye becomes red, sensitive to light, or painful, or develops a change in vision.

Copyright © 2009 Wolters Kluwer Health.


See Also...